Author Manuscript

SCHOLARONE™
Manuscripts

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of record](#). Please cite this article as [doi:10.1002/ana.25222](https://doi.org/10.1002/ana.25222).

The epilepsy phenotypic spectrum associated with a recurrent *CUX2* variant

Running head: *CUX2* and epilepsy with intellectual disability

Nicolas Chatron, MD¹, Rikke S. Møller, Ph.D², Neena L. Champaigne, MD³, Amy L. Schneider MGenCouns⁴, Alma Kuechler⁵, Audrey Labalme, MS¹, Thomas Simonet, MD, PhD⁶, Lauren Baggett, MS³, Claire Bardel, PhD⁷, Erik-Jan Kamsteeg, Ph.D⁸, Rolph Pfundt, Ph.D⁸, Corrado Romano, MD⁹, Johan Aronsson¹⁰, Antonino Alberti, MD⁹, Mirella Vinci⁹, Maria J. Miranda, MD, PhD¹¹, Amy Lacroix, BS¹², Dragan Marjanovic, MD², Vincent des Portes, MD, PhD¹³, Patrick Edery MD, PhD¹, Dagmar Wiczorek, MD, PhD^{5,14}, Elena Gardella MD², Ingrid E. Scheffer MBBS, PhD^{4,15,16}, Heather Mefford MD, PhD¹², Damien Sanlaville, MD, PhD¹, Gemma L. Carvill, PhD^{17*}, Gaetan Lesca, MD, PhD^{1*}

1. Department of Medical Genetics, Lyon University Hospital and GENDEV team CNRS UMR 5292, INSERM U1028, CRNL, and University Claude Bernard Lyon 1, GHE - Lyon - France.
2. Danish Epilepsy Centre, Dianalund, and University of Southern Denmark, Institute for Regional Health research, Odense, Denmark.
3. Greenwood Genetic Center, Greenwood, South Carolina, USA.
4. Epilepsy Research Centre, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia.
5. Institut für Humangenetik, Universitätsklinikum, and Universität Duisburg-Essen, Essen, Germany.
6. Service de Biostatistique-Bioinformatique, Lyon University Hospital, Lyon and CNRS UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, Villeurbanne, and University Claude Bernard Lyon 1, Lyon, France.
7. Centre de Biotechnologie Cellulaire, Hospices Civils de Lyon, Lyon, and Nerve-Muscle Interactions Team, Institut NeuroMyoGène CNRS UMR 5310 - INSERM U1217 - Université Claude Bernard Lyon 1, France.
8. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
9. Oasi Research Institute – IRCCS, Troina, Italy.
10. Habiliteringscentrum, Ryhov hospital, Jönköping, Sweden.
11. Department of Pediatrics, Pediatric Neurology, Herlev University Hospital, Copenhagen, Denmark
12. Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA 98195 USA.
13. Centre de référence « Déficiences Intellectuelles de causes rares », HCL, F-69675, Bron ; ISC, CNRS UMR 5304, F-69677, Bron ; Université de Lyon, F-69008, Lyon, France.
14. Institut für Humangenetik, Universitätsklinikum Essen, Essen, and Institut für Humangenetik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
15. Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.

16. Department of Paediatrics, Royal Children's Hospital, The University of Melbourne, Parkville, Victoria, Australia.

17. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.

*These two authors contributed equally to this work.

Correspondance to:

Gaetan Lesca, Service de Génétique, Groupement Hospitalier Est, 59 boulevard Pine, 69677 Bron, France. Tel: +33 4 72 12 96 39. Fax: +33 4 72 12 97 10. E mail: gaetan.lesca@chu-lyon.fr and Gemma Louise Carvill, Department of Neurology, Northwestern University Feinberg School of Medicine 303 East Chicago Avenue, Ward 9-183 312-503-6187 (ph), email: gemma.carvill@northwestern.edu

Type of manuscript: Reseach Article

Number of characters in title: 75/80

Number of characters in Running head: 46/50

Number of words: 2229/4500

Number of words in Abstract: 247/250

Number of words in Introduction: 298/500

Number of words in Discussion: 932/1500

Number of references: 26/50

Number of color figures: 2

Number of tables: 3

Abstract

Objective: Cut homeodomain transcription factor CUX2 plays an important role in dendrite branching, spine development, and synapse formation in layer II-III neurons of the cerebral cortex. We identify a recurrent *de novo* CUX2 p.Glu590Lys as a novel genetic cause for developmental and epileptic encephalopathy (DEE).

Methods: The *de novo* p.Glu590Lys variant was identified by whole-exome sequencing (n=5) or targeted gene panel (n=4). We performed electroclinical and imaging phenotyping on all patients.

Results: The cohort comprised 7 males and 2 females. Mean age at study was 13 years [0.5-21]. Median age at seizure onset was 6 months [2 months to 9 years]. Seizure types at onset were myoclonic, atypical absence with myoclonic components, and focal seizures. Epileptiform activity on EEG was seen in 8 cases: generalized polyspike-wave (6) or multifocal discharges (2). Seizures were drug-resistant in 7 or controlled with valproate (2). Six patients had a DEE: myoclonic DEE (3), Lennox-Gastaut syndrome (2) and West Syndrome (1). Two had a static encephalopathy and genetic generalized epilepsy, including absence epilepsy in one. One infant had multifocal epilepsy. Eight had severe cognitive impairment, with autistic features in six. The p.Glu590Lys variant affects a highly-conserved glutamine residue in the CUT domain predicted to interfere with CUX2 binding to DNA targets during neuronal development.

Interpretation: Patients with CUX2 p.Glu590Lys display a distinctive phenotypic spectrum which is predominantly generalized epilepsy, with infantile-onset myoclonic DEE at the severe end and generalized epilepsy with severe static developmental encephalopathy at the milder end of the spectrum.

Key words: intellectual disability; developmental and epileptic encephalopathy; myoclonic seizures; CUX2; CUT domain; *de novo* variant

INTRODUCTION

The developmental and epileptic encephalopathies (DEEs) are a group of severe infantile and childhood onset epilepsies characterized by developmental slowing or regression in the context of recurrent seizures and frequent interictal epileptiform discharges, often on a background of developmental delay¹. The DEEs have a wide range of etiologies, including both acquired and genetic causes. Considerable genetic heterogeneity has been demonstrated by recent advances in molecular genetics and next-generation sequencing, with more than 100 genes implicated, with various modes of inheritance. Identification of the pathogenic variant ends the diagnostic odyssey for patients and their families, provides information regarding prognosis and co-morbidities, and informs accurate genetic counselling. In addition, the identification of patients with a genetically defined epilepsy can allow therapeutic management to be optimized and pave the way to novel targeted approaches². Pathogenic variants in a subset of genes account for a significant proportion of patients with DEEs, such as *SCN1A*, *SCN2A*, *SCN8A*, *KCNQ2*, *STXBP1* and *CDKL5*, whereas many other genetic causes are rare³. For these rare genetic disorders, the small number of patients with pathogenic variants in single genes often requires international collaborations to identify multiple cases to facilitate careful delineation of the phenotype⁴.

The *de novo* c.1768G>A (p.Glu590Lys) missense variant in *CUX2* (NM_015267.3) was first reported in single cases from two large-scale whole-exome sequencing (WES) studies: one from a study of intellectual disability and the other a cohort of two specific DEEs, infantile spasms and Lennox-Gastaut syndrome^{5,6}. In this paper, we describe seven additional patients with the same recurrent p.Glu590Lys missense variant in *CUX2*, shown to be *de novo* in all cases. We present the clinical data for these nine patients and describe the phenotypic spectrum associated with this new recurrent genetic disorder which most frequently presents as a severe developmental and epileptic encephalopathy.

PATIENTS AND METHODS

This study was approved by the institutional review boards of the participating institutions. Informed consent was provided by the parent or the patient's legal guardian as all patients were minors or had intellectual disability. *CUX2* variants were identified by whole exome sequencing (n=2) or targeted gene panel sequencing (n=5) using previously described methods^{7,8} and were collated through the Matchmaker Exchange network⁴ or personal communication with colleagues.

We analyzed the clinical phenotype for the seven new patients as well as the two individuals previously reported^{5,6}. Seizure onset age, seizure types, EEG and neuroimaging findings were obtained, together with a history of each patient's developmental course.

3D modeling of structural effects was performed using either the *mutate_model* script in MODELLER⁹ or using the available solution structure for residues 544–631 (PDB 1X2L) for the CUT1 domain of *CUX2*. The resulting models were visualized using the SWISS-

PdbViewer¹⁰. The same 1X2L PDB file was also used as input for protein stability prediction applications: CUPSAT¹¹, I-mutant3.0¹², SNPs&GO^{3d13}. The web servers HOPE¹⁴, or PHYRE2¹⁵ were also used for in silico prediction of pathogenic variant effects on protein function. Multiple protein sequence alignments were done on Clustal Omega at EMBL-EBI server¹⁶.

RESULTS

Identification of patients with the p.Glu590Lys variant

Next generation sequencing identified a heterozygous *de novo* variant: Chr12:111748354G>A (hg19), c.1768G>A transition in *CUX2* in all seven patients. The c.1768G>A is predicted to lead to a substitution of the glutamate residue p. Glu590Lys. This variant has not been reported in the ExAC/gnomAD databases. Taken together with the two previously published cases, 2 individuals were identified through clinical diagnostic testing, 3/1222 through research studies in patients with DEE, and 4/2207 individuals were identified by screening of patient cohorts with intellectual disability with/without epilepsy.

Phenotype of patients with the *CUX2* Glu590Lys variant

Seven patients were male and 2 were female. Median age at study inclusion was 13 years [0.5-21](Table 1). Six of the nine patients had a DEE; whereas, two patients presented with a severe, static, developmental encephalopathy with genetic generalized epilepsy (GGE). Their GGE comprised absence seizures in one (patient 9) and early-onset absence epilepsy and myoclonic seizures in the other (patient 5). Patient 8 had focal epilepsy but, as he is only 6 months old, he is too young to predict his developmental outcome (Table 1). The pregnancy and perinatal period were unremarkable in all patients.

Median age at seizure onset was 6 months [range 2 months -9 years]. Seizure types at onset were myoclonic (n=4), absence (n=2), atypical absence with myoclonic components (2) and focal (n=3) including occipital (1), hemiclonic (1) and focal epileptic spasms (1). Generalized tonic-clonic seizures only occurred in one child at presentation. Apnea occurred with occipital seizures in one infant and with atypical absence seizures in another. Seizures were frequent at onset with multiple seizures per day. EEG was abnormal at seizure onset in all individuals; most frequently showing generalized spike-wave or polyspike-wave (n=5) (Table 2). Focal features were also noted including temporal discharges (n=1), occipital discharges (n=1), multifocal discharges (n=1), hypsarrhythmia (n=1) and focal slowing (n=1).

Valproate fully controlled seizures in two patients (Table 3). In patient 5, absence seizures were initially well controlled on valproate until an episode of non-convulsive status epilepticus at age three years, with rare episodes occurring every few years. The remaining five patients were refractory to multiple anti-epileptic drugs, including valproate. With the evolution of their epilepsy, multiple seizure types often emerged including myoclonic seizures (n=5), absence (n=5) and generalized tonic-clonic seizures (n=5).

EEG studies at follow-up showed variable features including generalized spike-wave (GSW) (5), focal or multifocal discharges (2) and background slowing (4) (Table 2). The EEG was normal in patient 9 who was seizure free. Myoclonic seizures were recorded with GSW or GPSW.

Seven of the 9 patients had severe intellectual disability and were non-verbal; one had profound impairment (Table 3). The remaining patient is currently 6 months old so his outcome is unclear. Seven patients could walk. Patients 2 and 4 experienced marked developmental regression during childhood, not related to frequent seizures or epileptiform activity. Two patients had autistic features. Movement disorders were seen in five cases, often comprising stereotypies such as hand-flapping, dyskinesia or athetosis. In three patients inappropriate episodes of laughter were observed, these episodes did not have an EEG correlate in two individuals and were not thought to be epileptic in origin. Brain MRI was normal in 6/9 individuals; findings in the remaining three patients showed cerebellar atrophy (1), hippocampal asymmetry (n=1) and a thin corpus callosum (n=1).

***In silico* analysis of the p.Glu590Lys pathogenic variant**

The p.Glu590Lys missense variant is located within the third alpha helix of the first DNA-binding CUT domain (IPR003350) (Fig 1A). This residue is highly conserved among orthologues (Fig 1B). Moreover, the negative charge at this residue seems particularly important, as it is conserved among all CUT domains, and up to the homologous domain Cro/C1-type helix-turn-helix domain (IPR001387) from Repressor protein cI of bacteriophages lambda (Fig 1C). This variant was predicted to be damaging by several computational tools (SIFT=0.001, Polyphen-2=1, fathmm-MKL_coding_score=0.985, CADD=33.0). Additionally, the SNPs&GO^{3d} tool, which combines structural information from the 1X2L crystal structure and Gene Ontology terms, classified the variant as disease associated.

Computational modeling using the available crystal structure for the first CUT domain (1X2L) suggested the substitution causes no major change in the alpha helix (Fig 2A). The conformation of the CUT1 domain of CUX2 relative to the DNA is not yet known. However, the CUT1 domain of human homeobox protein CUX2 (1X2L) has been crystalized. Also the rat HNF6 α CUT and Homeobox domains (2D5V) have been crystalized along with the DNA sequence of a specific promoter. The E54 residue (1X2L) and D41 residue (2D5V), homologues of the Glu590 are located in the middle of the third helix (Fig 2B), directly facing the major groove of the DNA helix (Fig 2C).

Analysis using the HOPE prediction tool showed that salt bridges are normally formed between amino acid positions 594 and 596 that will be disrupted by the pathogenic variant. The lysine residue is also larger and is positively charged, while wildtype glutamine has a negative charge. Calculations of protein stability using various prediction tools, suggested this substitution could lead to destabilization of CUX2 (CUPSAT: $\Delta\Delta G = -0.17$ kcal/mol, I-mutant3.0: $\Delta\Delta G = -0.85$ kcal/mol).

DISCUSSION

In this study, we describe a recurrent *de novo* missense variant p.Glu590Lys in *CUX2* as a novel cause for DEE in the majority of patients. All patients carry the same recurrent missense variant, suggesting an important role for this residue in *CUX2* function. Based on the ExAC dataset, *CUX2* is generally intolerant to variation; the probability of Loss-of-function intolerance score is very high (pLI= 1), as it is for missense variants (Z-score= 3.61) in *CUX2*.¹⁷ Since the same pathogenic variant has occurred independently in nine patients, and that *CUX2* is intolerant to genetic variation, we hypothesize that this amino acid position plays a specific role in the pathophysiologic process. The predominant phenotype was an infantile-onset myoclonic DEE with a phenotypic DEE spectrum that extended to Lennox-Gastaut syndrome and infantile spasms, as well as a static developmental encephalopathy with genetic generalized epilepsy.

Infantile onset of seizures was usual with a median onset of six months. Myoclonic seizures or absence seizures with a myoclonic component were the most frequent type of seizures at onset (5/9). Absence seizures were also prominent, especially in the two cases with developmental encephalopathy, who did not have evidence for an epileptic encephalopathy. This is distinguished by developmental delay leading to intellectual disability, without plateauing or regression of development, and associated with epilepsy¹. One had episodes of non-convulsive status epilepticus but these were rare and not associated with developmental slowing; however, it does suggest a more severe form of absence epilepsy, as can be observed in early-onset absence epilepsy (defined as onset under four years)^{17, 18}.

In general, seizures were refractory to multiple AEDs, although two cases were seizure free on valproate. Additional seizure types often evolved and included atypical absences, tonic, and generalized tonic-clonic seizures. Focal seizures were rare.

The majority of patients with the p.Glu590Lys recurrent *de novo* variant had severe to profound intellectual disability, with developmental regression observed in two cases. The majority were non-verbal but could walk. Additional features included movement disorders with stereotypies such as hand-flapping and dyskinesia, autistic features and inappropriate non-epileptic laughing episodes. This severe cognitive impairment is due to a developmental component, together with a superimposed epileptic encephalopathy in those with a DEE. This developmental component is illustrated by early developmental delay in some cases, prior to seizure onset, and by the two individuals with severe ID without a DEE.

Cux2 and its orthologue Cux1 encode the vertebrate homologs of the *Drosophila* homeobox DNA-binding transcription factor Cut^{19, 20}. Despite their divergent evolution, Cux1 and Cux2 exhibit high sequence conservation within specific protein regions, notably the Cut repeat domains. Whereas Cux1 is expressed in most tissues, Cux2 is expressed primarily in neuronal tissues during development and continues to be expressed in post-mitotic neurons, where it is a marker of the upper layer II-III neurons²¹. Cux2^{-/-} knock-out mice had normal cortical organization. Similar to these findings, there were no obvious structural or organizational

abnormalities in the majority of patients as brain MRI was normal or showed mild nonspecific features (n=3). However, *Cux2*^{-/-} knock-out mice displayed decreased dendritic length as well as reduction in the number of branches, density of spines, and synaptic function in the layer II-III neurons^{22, 23}. These abnormal dendrites and synapses in *Cux2*^{-/-} mice correlate with reduced synaptic function and defects in working memory, though seizures were not reported²⁴. The intellectual disability phenotypes observed in patients may be related to putative abnormal dendritic branching or function, especially in layer II-III neurons of brain cortex, as seen in *Cux2* knockout mice.

The CUX2 p.Glu590Lys pathogenic variant is located in the first alpha helix of the CUT domain 1 (CR1). This protein domain plays an important role in the binding of CUX2 to its DNA targets, where it controls gene expression as a transcription factor. Our *in-silico* analyses point toward a destabilization effect in the presence of the mutant lysine residue. This change to a highly conserved positive charge (lysine) could therefore alter the interaction with the negatively charged DNA's phosphate backbone. Interestingly no loss-of-function (truncating) variants have been observed in patients nor controls, suggesting complete loss of CUX2 function may be lethal. Collectively, these results suggest that the p.Glu590Lys pathogenic variant alters either the stability or specificity of the interaction of CUX2 with the DNA, which is known to be transient²⁵. This may confer a partial loss of function effect for the p.Glu590Lys variant. Alternatively, another possibility is that this variant confer gain of function or dominant negative properties, in which the mutant protein has an inhibitory interaction on the normal allele, or binds ectopic target DNA regions. In order to determine the functional effect of this missense variant functional studies in CUX2 knockout and the CUX2 p.Glu590Lys variant *in vitro* and *in vivo* need to be performed.

Our study highlights the importance of international collaborative efforts to identify novel genes implicated in epilepsy, which are likely to be rare overall and thus require large cohorts of patients to identify recurrent mutations in genes. Moreover, until now, novel gene discovery in epilepsy has largely focused on truncating variants, partly because these variants are easier to interpret in the context of a haploinsufficient model. However, in accordance with a recent study that included molecular data from patients 6 and 9, the present study emphasizes the importance of recurrent missense variation in neurodevelopmental disorders, including intellectual disability and epilepsy²⁶. This observation has also been illustrated in the epilepsies in a recent study that identified a recurrent missense mutation in a more common epilepsy gene, *SCN1A*, that produced a profound phenotype, far more severe than the well-established Dravet syndrome presentation of this gene⁷. In addition, the role of missense mutations in DEE, and especially recurrent ones, has been emphasized in another recent paper²⁷. The study of recurrent pathogenic missense variation provides a unique avenue to understand the role of a protein (and its domains) in neuronal development and function. Future functional studies will be important to understand the pathophysiological process of this specific CUX2 pathogenic variant, but also the function of CUX2.

ACKNOWLEDGEMENTS

The authors would like to thank the families for their participation. We thank the NGS platform of the University Hospital of Lyon (Hospices Civils de Lyon). GLC is supported by NIH NINDS NS089858, and a CURE Taking Flight Award. Work on patient 9 was supported by the Italian Ministry of Health and '5 per mille' funding". HCM is supported by National Institutes of Health (NINDS grant NS069605). IES is supported by the National Health and Medical Research Council of Australia.

URLS

Clustal-Omega multiple sequence alignment: <http://www.ebi.ac.uk/Tools/msa/clustalo/>

SIFT: <http://sift.jcvi.org/>

Polyphen-2: <http://genetics.bwh.harvard.edu/pph2/>

CADD: <http://cadd.gs.washington.edu/>

Fathmm: <http://fathmm.biocompute.org.uk/>

GERP: <http://mendel.stanford.edu/SidowLab/downloads/gerp/>

HOPE: <http://www.cmbi.ru.nl/hope/about>

CUPSAT: <http://cupsat.tu-bs.de/>

denovo-db: <http://denovo-db.gs.washington.edu/denovo-db/>

Gnomad: <http://gnomad.broadinstitute.org/>

EXAC: <http://exac.broadinstitute.org/>

AUTHORS CONTRIBUTIONS

NC, GLC and GL contributed to the conception and design of the study. NC, RS, NLC, ALS, AK, AL, TS, LB, CB, EJK, RP, CR, JA, AA, MV, MJM, DM, VdP, PE, DW, EG, IES, DS, GLC and GL contributed to the acquisition and analysis of data. NC, ALS, EG, IES, HM, GLC, GL contributed to drafting the text and preparing the figures.

POTENTIAL CONFLICTS OF INTEREST

Nothing to report.

Table 1. Clinical features of the nine patients with the recurrent de novo p.Glu590Lys variant of *CUX2*

Patient n°	Sex	Age at study (years)	Age at first seizures (months)	Type(s) of seizures at onset	Evolution of seizures
Patient 1 ⁵	M	8	6	Focal spasms	Seizure free
Patient 2	M	19	7	Myoclonic seizures and right occipital seizures with apnea	30 months: 1 febrile tonic seizure. 3 years: 2 focal seizures. 4 years: Myoclonic seizures. 7 years: GTCS and myoclonic seizures
Patient 3	M	21	6	Atypical absences with myoclonus	Atypical absences, tonic seizures with myoclonic component, atonic seizures, GTCS
Patient 4	F	9	6	Myoclonic	Myoclonic seizures, tonic seizures, GTCS
Patient 5	F	14	12	Absence seizures	Myoclonic seizures. NCSE
Patient 6 ⁶	M	12	2	Myoclonic seizures	Atonic seizures, myoclonic and absence seizures with eye fluttering, GTCS
Patient 7	M	16	5	Myoclonic seizures	Myoclonic seizures, especially in the mornings, myoclonic drop attacks
Patient 8	M	0.5	2	GTCS, atypical absences with apnea and myoclonus, right hemiconic seizures	GTCS, Focal impaired awareness seizures, 1 febrile seizure after vaccination
Patient 9 ²⁶	M	14	108 (9 years)	Absence seizures	Seizure free from age 12

F = female; GTCS = generalized tonic-clonic seizures; M = male; NCSE = Nonconvulsive status epilepticus.

Table 2. EEG features of the nine patients with the recurrent de novo p.Glu590Lys variant of *CUX2*

Patient n°	EEG at onset	Later EEG studies	AEDs trialed	Current AEDs	Epilepsy syndrome
Patient 1 ⁵	Hypsarrhythmia	Not done	STM, VPA, Synacthen for 3 months with improvement	VPA	DEE: West syndrome
Patient 2	GSW, sometimes with myoclonic seizures. Right occipital seizure recorded	3 Hz GSW, absence seizures with myoclonic components	VPA, CLB	VPA	Myoclonic DEE
Patient 3	3-4 Hz GSW, GPSW	Background slowing, frequent trains of 1.5-2 Hz and 3-4 Hz GSW; myoclonic seizures with GSW	VPA, OXC, CBZ, LTG, VGB, ZNS, PHT, NZP	LEV, CLB, VPA, ZNS, VNS (beneficial)	DEE: Lennox-Gastaut syndrome
Patient 4	GSW, GPSW	Myoclonic seizures with GPSW. Tonic seizures with generalized polyspike	LEV, CZP, ESX, CBZ, LCM, RUF	ESX, CLB, LCM, RUF, ketogenic diet	DEE: Lennox-Gastaut syndrome
Patient 5	3 Hz GSW	Slow background, Absence seizure with 3 Hz GSW, fast irregular GSW, GPSW	VPA	VPA, LTG	Severe Developmental Encephalopathy with Genetic Generalised Epilepsy (early onset absence epilepsy and myoclonic seizures)
Patient 6 ⁶	Left temporal spikes/sharp waves	Slow background with multifocal epileptiform discharges	CBZ, VPA, CLB, ACZ, LTG, FBM, DZP, LEV, CZP, TPM, prednisolone, VNS, ketogenic diet	VPA, CZP, TPM	Myoclonic DEE
Patient 7	GSW, GPSW	GSW with myoclonic seizure. During sleep, continuous 1-2 Hz GSW	CBZ, VPA, ACZ, LTG, TPM, CZP, LEV, RUF, LCM, CLB, PER	VPA, CLB, STP	Myoclonic DEE
Patient 8	Multifocal discharges, mainly independent bi-parieto-temporal	Slowing and sharp waves in the left temporal region	VPA, DZP, PB, LEV	VPA	Multifocal epilepsy, too early to diagnose DEE
Patient 9 ²⁶	Left fronto-central slowing	Normal EEG	VPA	VPA	Severe Developmental Encephalopathy with absence epilepsy

ACZ = Acetazolamide; AED = anti-epileptic drug; CBZ = carbamazepine; CLB = Clobazam; CZP = Clonazepam; DEE = Developmental and Epileptic Encephalopathy; DZP = Diazepam; ESX = Ethosuximide; FBM = Felbamate; GSW = generalized spike-wave; GPSW = generalized polyspike-wave; LCM = lacosamide; LEV = Levetiracetam; LTG = lamotrigine; MDZ = Midazolam; NZP = nitrazepam; OXC = Oxcarbazepine; PB = Phenobarbitone; PHT = phenytoin; PER = perampanel; RUF = Rufinamide; STM = Sulthiame; STP = Stiripentol; TPM = Topiramate; VGB = Vigabatrin; VNS = vagal nerve stimulation; VPA = valproate; ZNS = Zonisamide.

Table 3. Other characteristics of the nine patients with the recurrent de novo p.Glu590Lys variant of CUX2

Patient n°	Brain MRI (age)	Head circumference (age)	Intellectual disability	Other neurological features
Patient 1 ⁵	Normal (8 mo)	50 cm (7 years, 50 th centile)	Severe	Non verbal, Movement disorder: stereotypies (hand flapping)
Patient 2	Normal (8 mo)	51 cm (13 years, 25 th centile)	Never normal, Regression at 7 months and at 12 years. Profound	Non-verbal Movement disorder: athetosis, dystonia, stereotypies. Hypotonic at 1 year, then spastic tetraparesis from 12 years with loss of ambulation.
Patient 3	Cerebellar atrophy (6 mo)	56 cm (21 years, 73 rd percentile)	Severe	Non-verbal. No eye contact, inappropriate laughter episodes
Patient 4	Hippocampal asymmetry (6yr 3mo)	52 cm (9 years, 44 th percentile)	Never normal, severe regression at 8 years. Severe	Non-verbal. Decreased reflexes, ataxic gait
Patient 5	Normal (5 yr)	54 cm (14 years, 50 th centile)	Severe	Movement disorder: stereotypies (hand flapping), obsessional features
Patient 6 ⁶	Normal (6mo)	51 cm (7 years, 50 th centile)	Severe	Ataxic gait, Movement disorder: stereotypies (hand flapping), inappropriate laughter episodes
Patient 7	Normal (16mo, 15 yr)	49,5 cm (3,5 years, 25 th centile)	Severe	Non-verbal, autistic features
Patient 8	Normal (15 yr)	41 cm (0.5 years, 15 th centile)	Too young to assess	Movement disorder: dyskinesia, inappropriate laughter spells, mild hypotonia
Patient 9 ²⁶	Thin posterior corpus callosum (5yr 8mo)	54 cm (14 years, 50 th centile)	Severe	Non-verbal, Autistic features

Mo = months, yr =years

FIGURE LEGENDS

Figure 1. The recurrent Glu590Lys pathogenic missense variant and CUX2 structure.

A. The CUX2 protein consists of three DNA-binding CUT domains (pink) and a single homeodomain (blue). Vertical lines below the protein show the location of missense variants that are reported more than twice in the Gnomad dataset. The CUX2 p.Glu590Lys pathogenic variant lies in the first CUT domain, these CUT domains are largely devoid of missense variants in the general population (data from gnomAD).

B. The glutamine residue at amino acid position 590 (blue arrow) is fully conserved among cut-like Homeobox proteins across 19 species using Clustal alignment. GERP score GERP++=4.770, phyloP100way Vertebrate=9.998, phastCons100way Vertebrate=1.000).

C. High conservation of a negatively charged amino acid in third helix of all human CUT domains (IPR003350), as well as in related Cro/C1-type helix-turn-helix domain (IPR001387) (blue arrow). Clustal alignment of CUT domains of human ONECUT, SATB and CUX proteins, along with the H-L-H domain of bacteriophage lambda RPC1.

Figure 2. In silico predictions of the consequences of the p.Glu590Lys.

A. Glu590 in CUT1 domain lies in the 3rd helix of the CUT domain. Sequence Chain View of 1X2L Solution structure of the first CUT domain of human homeobox protein CUX2 (Cut-like 2). Alpha helix is not obviously modified by the Glu to Lys mutation. pdb-viewer superposition of 1X2L and the structure generated by MODELLER mutate_model.py script.

B. Similar position in third helix of E54 in 1X2L structure (CUT domain of human homeobox protein CUX2) and D41 in 2D5V structure (rat HNF-6alpha DNA-binding domain in complex with the TTR promoter), as reported on PDB (<http://www.ebi.ac.uk/pdbe/>)

C. Three 3D views of 2D5V structure, from <http://www.rcsb.org/pdb>, showing the position of D41 within the major groove of DNA.

References:

1. Scheffer IE. A new classification and class 1 evidence transform clinical practice in epilepsy. *Lancet Neurol.* 2017 Jan;17(1):7-8.
2. Consortium E. A roadmap for precision medicine in the epilepsies. *Lancet Neurol.* 2015 Dec;14(12):1219-28.
3. Lesca G, Rudolf G, Labalme A, et al. Epileptic encephalopathies of the Landau-Kleffner and continuous spike and waves during slow-wave sleep types: genomic dissection makes the link with autism. *Epilepsia.* 2012;53(9):1526-38.
4. Philippakis AA, Azzariti DR, Beltran S, et al. The Matchmaker Exchange: a platform for rare disease gene discovery. *Hum Mutat.* 2015 Oct;36(10):915-21.
5. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet.* 2012.
6. Allen AS, Berkovic SF, Cossette P, et al. De novo mutations in epileptic encephalopathies. *Nature.* 2013 Sep 12;501(7466):217-21.
7. Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nat Genet.* 2013 Jul;45(7):825-30.
8. Berryer MH, Hamdan FF, Klitten LL, et al. Mutations in SYNGAP1 Cause Intellectual Disability, Autism and a Specific form of Epilepsy by Inducing Haploinsufficiency. *Human mutation.* 2012.
9. Webb B, Sali A. Protein Structure Modeling with MODELLER. *Methods Mol Biol.* 2017;1654:39-54.
10. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis.* 1998 Dec;18(15):2714-23.
11. Parthiban V, Gromiha MM, Schomburg D. CUPSAT: prediction of protein stability upon point mutations. *Nucleic Acids Res.* 2006 Jul 01;34(Web Server issue):W239-42.
12. Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. *Nucleic Acids Res.* 2005 Jul 01;33(Web Server issue):W306-10.
13. Capriotti E, Calabrese R, Fariselli P, Martelli PL, Altman RB, Casadio R. WS-SNPs&GO: a web server for predicting the deleterious effect of human protein variants using functional annotation. *BMC genomics.* 2013;14 Suppl 3:S6.
14. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics.* 2010;11:548.
15. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein modeling, prediction and analysis. *Nature protocols.* 2015 Jun;10(6):845-58.
16. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Molecular systems biology.* 2011 Oct 11;7:539.
17. Suls A, Mullen SA, Weber YG, et al. Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. *Ann Neurol.* 2009;66(3):415-9.
18. Taylor I, Berkovic SF, Scheffer IE. Genetics of epilepsy syndromes in families with photosensitivity. *Neurology.* 2013 Apr 2;80(14):1322-9.
19. Quaggin SE, Heuvel GB, Golden K, Bodmer R, Igarashi P. Primary structure, neural-specific expression, and chromosomal localization of Cux-2, a second murine homeobox gene related to *Drosophila cut*. *J Biol Chem.* 1996 Sep 13;271(37):22624-34.
20. Sansregret L, Nepveu A. The multiple roles of CUX1: insights from mouse models and cell-based assays. *Gene.* 2008 Apr 15;412(1-2):84-94.
21. Yamada M, Clark J, McClelland C, Capaldo E, Ray A, Iulianella A. Cux2 activity defines a subpopulation of perinatal neurogenic progenitors in the hippocampus. *Hippocampus.* 2014 Feb;25(2):253-67.

22. Cubelos B, Sebastian-Serrano A, Kim S, et al. Cux-2 controls the proliferation of neuronal intermediate precursors of the cortical subventricular zone. *Cerebral cortex* (New York, NY : 1991). 2008 Aug;18(8):1758-70.
23. Cubelos B, Sebastian-Serrano A, Kim S, Redondo JM, Walsh C, Nieto M. Cux-1 and Cux-2 control the development of Reelin expressing cortical interneurons. *Developmental neurobiology*. 2008 Jun;68(7):917-25.
24. Cubelos B, Sebastian-Serrano A, Beccari L, et al. Cux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layer neurons of the cortex. *Neuron*. 2010 May 27;66(4):523-35.
25. Gingras H, Cases O, Krasilnikova M, Berube G, Nepveu A. Biochemical characterization of the mammalian Cux2 protein. *Gene*. 2005 Jan 3;344:273-85.
26. Geisheker MR, Heymann G, Wang T, et al. Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains. *Nat Neurosci*. 2017 Aug;20(8):1043-51.
27. Hamdan FF, Myers CT, Cossette P, et al. High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. *Am J Hum Genet*. 2017 Nov 2;101(5):664-85.

Author Manuscript

Figure 1. The recurrent Glu590Lys pathogenic missense variant and CUX2 structure.

A. The CUX2 protein consists of three DNA-binding CUT domains (pink) and a single homeodomain (blue). Vertical lines below the protein show the location of missense variants that are reported more than twice in the GnomAD dataset. The CUX2 p.Glu590Lys pathogenic variant lies in the first CUT domain, these CUT domains are largely devoid of missense variants in the general population (data from gnomAD).

B. The glutamine residue at amino acid position 590 (blue arrow) is fully conserved among cut-like Homeobox proteins across 19 species using Clustal alignment. GERP score GERP++=4.770, phyloP100way Vertebrate= 9.998, phastCons100way Vertebrate =1.000).

C. High conservation of a negatively charged amino acid in third helix of all human CUT domains (IPR003350), as well as in related Cro/C1-type helix-turn-helix domain (IPR001387) (blue arrow). Clustal alignment of CUT domains of human ONECUT, SATB and CUX proteins, along with the H-L-H domain of bacteriophage lambda RPC1.

213x254mm (300 x 300 DPI)

Author Manuscript

Figure 2. In silico predictions of the consequences of the p.Glu590Lys.

A. Glu590 in CUT1 domain lays in the 3rd helix of the CUT domain. Sequence Chain View of 1X2L Solution structure of the first CUT domain of human homeobox protein CUX2 (Cut-like 2). Alpha helix is not obviously modified by the Glu to Lys mutation. pdb-viewer superposition of 1X2L and the structure generated by MODELLER mutate_model.py script.

B. Similar position in third helix of E54 in 1X2L structure (CUT domain of human homeobox protein CUX2) and D41 in 2D5V structure (rat HNF-6alpha DNA-binding domain in complex with the TTR promoter), as reported on PDB (<http://www.ebi.ac.uk/pdbe/>))

C. Three 3D views of 2D5V structure, from <http://www.rcsb.org/pdb> , showing the position of D41 within the major groove of DNA.

190x254mm (300 x 300 DPI)

Author Manuscript

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Chatron, N;Moller, RS;Champaigne, NL;Schneider, AL;Kuechler, A;Labalme, A;Simonet, T;Baggett, L;Bardel, C;Kamsteeg, E-J;Pfundt, R;Romano, C;Aronsson, J;Alberti, A;Vinci, M;Miranda, MJ;Lacroix, A;Marjanovic, D;des Portes, V;Edery, P;Wieczorek, D;Gardella, E;Scheffer, IE;Mefford, H;Sanlaville, D;Carvill, GL;Lesca, G

Title:

The epilepsy phenotypic spectrum associated with a recurrent CUX2 variant

Date:

2018-05-01

Citation:

Chatron, N., Moller, R. S., Champaigne, N. L., Schneider, A. L., Kuechler, A., Labalme, A., Simonet, T., Baggett, L., Bardel, C., Kamsteeg, E. -J., Pfundt, R., Romano, C., Aronsson, J., Alberti, A., Vinci, M., Miranda, M. J., Lacroix, A., Marjanovic, D., des Portes, V. ,... Lesca, G. (2018). The epilepsy phenotypic spectrum associated with a recurrent CUX2 variant. ANNALS OF NEUROLOGY, 83 (5), pp.926-934. <https://doi.org/10.1002/ana.25222>.

Persistent Link:

<http://hdl.handle.net/11343/283838>